RSV = Big Sales ?30 Jun 2023 10:16
RSV: The director of the U.S. Centers for Disease Control and Prevention signed off on the use of new vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections in older adults.
Tony Wood, Chief Scientific Officer, GSK, said: “GSK’s successful development of an RSV vaccine to help protect older adults from RSV lower respiratory tract disease (LRTD) represents a major scientific advance, resulting from years of collaboration across academia, industry, and research centres. We are grateful to the ACIP and CDC for recognising the potential of Arexvy and look forward to partnering with public health officials, healthcare professionals and payers to make it available for eligible older adults in the US before this year’s RSV season begins.”
There are an estimated 55.8 million people aged 65 and older in the US1 who are at increased risk of RSV, a common, contagious virus that can lead to serious respiratory illness.2 RSV causes approximately 177,000 hospitalisations and an estimated 14,000 deaths in this age group in the US each year. For adults 60 and older, data suggest an increased risk for severe RSV infection that can lead to hospitalisation. Older adults, including those with underlying medical conditions*, such as chronic heart disease, chronic lung disease or diabetes, are at high risk of severe RSV illness and account for the majority of RSV hospitalisations.